J
Jeannette Y. Lee
High Impact
Professor
faculty
Biostatistics, College of Medicine
57 h-index
248 pubs
10,239 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Jeannette Y. Lee, Professor of Biostatistics at the University of Arkansas for Medical Sciences, leads a research group focused on health outcomes and disease prevention, particularly within populations affected by HIV.
Her work includes investigations into the treatment and prevention of anal high-grade squamous intraepithelial lesions (HSIL) and anal cancer among individuals living with HIV, as evidenced by her publications on the ANCHOR study and HPV vaccination. Lee has also published on the treatment outcomes for HIV-related Hodgkin lymphoma and the safety of specific cancer therapies in people living with HIV. Her research extends to the prevalence of oral HPV infections in specific populations and the predictive value of serum biomarkers for advanced cancers in resource-limited settings.
Lee's scholarship metrics include an h-index of 57, with over 10,155 citations across 247 publications. She is recognized as a highly cited researcher and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Jessica Snowden, Songthip Ounpraseuth, Zhuopei Hu, and Milan Bimali.
Metrics
- h-index: 57
- Publications: 248
- Citations: 10,239
Selected Publications
-
A novel methodology for using light-scattering sensors to measure indoor particulate matter in a multi-site clinical trial (2026)
-
Retention, blinding, and health outcomes from a rural pediatric obesity feasibility randomized control trial (2026)
-
Accelerated Weaning of Opioids to Reduce Pharmacologic Exposure for Neonatal Opioid Withdrawal Syndrome: A Randomized Clinical Trial (2026)
-
Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01) (2025)
-
Comparing Medical Record Abstraction (MRA) error rates in an observational study to pooled rates identified in the data quality literature (2024)
-
Error rates of data processing methods in clinical research: A systematic review and meta-analysis of manuscripts identified through PubMed (2024)
-
Infant Feeding and Weight Trajectories in the Eat, Sleep, Console Trial (2024)
-
Influence of Eat, Sleep, and Console on Infants Pharmacologically Treated for Opioid Withdrawal (2024)
-
Bronchiolitis recovery and the use of High Efficiency Particulate Air (HEPA) Filters (The BREATHE Study): study protocol for a multi-center, parallel, double-blind, randomized controlled clinical trial (2024)
-
Correction: Improving pediatric COVID-19 vaccine uptake using an mHealth tool (MoVeUp): study protocol for a randomized, controlled trial (2024)
-
Validation of remote anthropometric measurements in a rural randomized pediatric clinical trial in primary care settings (2024)
-
Error Rates of Data Processing Methods in Clinical Research: A Systematic Review and Meta-Analysis of Manuscripts Identified Through PubMed (2023)
-
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study (2023)
-
Vitamin D Oral Replacement in Children With Obesity Related Asthma: <scp>VDORA1</scp> Randomized Clinical Trial (2023)
-
Two-Year Incidence and Cumulative Risk and Predictors of Anal High-Grade Squamous Intraepithelial Lesions (Anal Precancer) Among Women With Human Immunodeficiency Virus (2023)
Grants & Funding
- Sexually Transmitted Infections Clinical Trials Group - BRAVO Study Opt 2 NIH/Nat. Inst. of Allergy & Infectious Diseases - Pass Through: University of Alabama at Birmingham Principal Investigator
- Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials Network NIH Co-Principal Investigator
- No FP attached UAMS College of Medicine Principal Investigator
- ECHO Administrative Supplement - Neonatal Opioid Trials (ESC Protocol) NIH/Office of the Director - Pass Through: Duke University Principal Investigator
- AIDS Malignancy Consortium (AMC) Statistical Center - Continuation Year 2022-2023 NIH/Nat. Cancer Institute - Pass Through: Icahn School of Medicine at Mount Sinai Principal Investigator
- AMC Statistical Center - Latin America Supplement - Continuation Year 2019-2020 - Continuation NIH/Nat. Cancer Institute - Pass Through: University of California, Los Angeles Principal Investigator
- Statistical Center for the STI CTG NIH/Nat. Inst. of Allergy & Infectious Diseases - Pass Through: University of Alabama at Birmingham Principal Investigator
- No FP attached UAMS College of Medicine Principal Investigator
Collaboration Network
Top Collaborators
Ronald T. Mitsuyasu
23 shared publications
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
- Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 23 shared publications
Elizabeth Y. Chiao
22 shared publications
- High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus
- Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Two-Year Incidence and Cumulative Risk and Predictors of Anal High-Grade Squamous Intraepithelial Lesions (Anal Precancer) Among Women With Human Immunodeficiency Virus
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 22 shared publications
David M. Aboulafia
22 shared publications
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 22 shared publications
Joseph A. Sparano
21 shared publications
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 21 shared publications
Lee Ratner
20 shared publications
- Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 20 shared publications
Richard F. Ambinder
20 shared publications
- Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 20 shared publications
Robert A. Baiocchi
20 shared publications
- Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 20 shared publications
Missak Haigentz
19 shared publications
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Table 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 19 shared publications
William Wachsman
19 shared publications
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Table 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 19 shared publications
Michelle A. Rudek
19 shared publications
- Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
- Supplementary Table 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Showing 5 of 19 shared publications
Jessica Snowden
University of Arkansas for Medical Sciences
13 shared publications
In database
- Error Rates of Data Processing Methods in Clinical Research: A Systematic Review and Meta-Analysis of Manuscripts Identified Through PubMed
- Active vs Traditional Methods of Recruiting Children for a Clinical Trial in Rural Primary Care Clinics
- Vitamin D Oral Replacement in Children With Obesity Related Asthma: <scp>VDORA1</scp> Randomized Clinical Trial
- Rationale and protocol for a cluster randomized, cross-over trial of recruitment methods of rural children in primary care clinics: A feasibility study of a pediatric weight control trial in the IDeA States Pediatric Clinical Trials Network
- Protocol for the Vitamin D Oral Replacement in Asthma (VDORA) study
Showing 5 of 13 shared publications
Alan E. Simon
National Center for Health Statistics (US)
9 shared publications
- Error Rates of Data Processing Methods in Clinical Research: A Systematic Review and Meta-Analysis of Manuscripts Identified Through PubMed
- Active vs Traditional Methods of Recruiting Children for a Clinical Trial in Rural Primary Care Clinics
- Vitamin D Oral Replacement in Children With Obesity Related Asthma: <scp>VDORA1</scp> Randomized Clinical Trial
- Rationale and protocol for a cluster randomized, cross-over trial of recruitment methods of rural children in primary care clinics: A feasibility study of a pediatric weight control trial in the IDeA States Pediatric Clinical Trials Network
- Pragmatic, randomized, blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS)
Showing 5 of 9 shared publications
Maryam Y. Garza
University of Arkansas for Medical Sciences (US)
9 shared publications
- Error Rates of Data Processing Methods in Clinical Research: A Systematic Review and Meta-Analysis of Manuscripts Identified Through PubMed
- Vitamin D Oral Replacement in Children With Obesity Related Asthma: <scp>VDORA1</scp> Randomized Clinical Trial
- Measuring and Controlling Medical Record Abstraction (MRA) Error Rates in an Observational Study
- Bronchiolitis recovery and the use of High Efficiency Particulate Air (HEPA) Filters (The BREATHE Study): study protocol for a multi-center, parallel, double-blind, randomized controlled clinical trial
- Comparing Medical Record Abstraction (MRA) Error Rates in an Observational Study to Pooled Rates Identified in the Data Quality Literature
Showing 5 of 9 shared publications
Shelly Lensing
St. Jude Children's Research Hospital (US)
8 shared publications
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus
- Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV
- Prevalence of oral human papillomavirus infection among Indian HIV-positive men who have sex with men: a cross-sectional study
- Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
Showing 5 of 8 shared publications
Joel M. Palefsky
University of California, San Francisco (US)
8 shared publications
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus
- Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV
- Prevalence of oral human papillomavirus infection among Indian HIV-positive men who have sex with men: a cross-sectional study
- AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent Vaccine in Indian Women Living With HIV
Showing 5 of 8 shared publications
Similar Researchers
Based on overlapping research topics
Jeanette Y. Lee
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health disparities and outcomes
Lymphoma Diagnosis and Treatment
Maribel Tirado Gomez
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health disparities and outcomes
Cervical Cancer and HPV Research
Juan de la Ossa
University of Arkansas for Medical Sciences
HIV/AIDS Research and Interventions
Cancer Treatment and Pharmacology
Health disparities and outcomes
Jessica D. Korman
University of Arkansas for Medical Sciences
HIV/AIDS Research and Interventions
Cancer Treatment and Pharmacology
Health disparities and outcomes
Jeanette Y. Lee
University of Arkansas for Medical Sciences
HIV/AIDS Research and Interventions
Cancer Treatment and Pharmacology
Health disparities and outcomes
Don Vena
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health disparities and outcomes
Cervical Cancer and HPV Research